Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

ADC Therapeutics (ADCT) Short term Debt: 2020-2022

Historic Short term Debt for ADC Therapeutics (ADCT) over the last 2 years, with Dec 2022 value amounting to $12.5 million.

  • ADC Therapeutics' Short term Debt rose 89.72% to $12.5 million in Q4 2022 from the same period last year, while for Dec 2022 it was $12.5 million, marking a year-over-year increase of 89.72%. This contributed to the annual value of $12.5 million for FY2022, which is 89.72% up from last year.
  • Per ADC Therapeutics' latest filing, its Short term Debt stood at $12.5 million for Q4 2022, which was up 89.78% from $6.6 million recorded in Q2 2022.
  • In the past 5 years, ADC Therapeutics' Short term Debt ranged from a high of $12.5 million in Q4 2022 and a low of $2,642 during Q3 2020.
  • Moreover, its 3-year median value for Short term Debt was $6.5 million (2022), whereas its average is $5.4 million.
  • Data for ADC Therapeutics' Short term Debt shows a peak YoY soared of 248,764.50% (in 2021) over the last 5 years.
  • ADC Therapeutics' Short term Debt (Quarterly) stood at $2,642 in 2020, then soared by 248,764.50% to $6.6 million in 2021, then surged by 89.72% to $12.5 million in 2022.
  • Its Short term Debt stands at $12.5 million for Q4 2022, versus $6.6 million for Q2 2022 and $6.5 million for Q1 2022.